Key Word Submission Number(s)
(2R,6R)-hydroxynorketamine P354
(R,S)-ketamine P250, P354, P365, P726
(R,S)-ketamine infusion therapy P335
11β-hydroxylase inhibitor P148
17-β-estradiol P197, P314
22q11 51
22q11 deletion syndrome 51.4, P75, P516, P568, P573
22q11.2 CNV P539
22q11.2 deletion syndrome P487
2-AG 56.4, P88, P559
2-photon techniques P751
3-hydroxykynurenine P579
5-HT P83, P265
5-HT1A receptors P607
5-ht1b 52.3
5-HT2A receptor P360, P459
5-HT2A receptors P405
5-HT4 receptor P81
7 Tesla fMRI P534
7T fMRI P429
7T MRS P64, P185, P283, P534
a4b2 nicotinic acetylcholine receptors P673
ABCD P141, P511
ABCD study P34, P136, P139, P162, P290
Abstinence P669
Abuse Liability P693
academic performance P139
acamprosate P681
accelerated aging P217
acetylcholine 1.5, 51, 51.3, P107, P381, P573
Acid-sensing P71
acoustic startle P568
acoustic startle response P474
Active Avoidance 56, 56.2, 56.4
Acute and Chronic Stress 34, P14, P86, P278, P483, P747
Acute dose P454
Acute Stress 31.2, 34.1, 34.4, P15, P66, P445, P630, P642, P666
Acute Traumatic Stress P59, P410
Acyl chain remodeling P300
Adaptive Behavior P206
Adaptive deep brain stimulation P235
addiction 9, 55.1, P56, P586, P643, P649, P670, P675, P723, P738
addiction circuitry P731, P732
Addictions Neuroclinical Assessment P658
ADHD 30, 30.1, 30.2, 44, 44.1, P119, P123, P158, P167, P173, P175, P291, P293, P424, P433, P443
adjunctive P343
Adjunctive cariprazine P436
Adolescence 21.1, P42, P78, P135, P139, P160, P178, P189, P190, P239, P280, P299, P626, P660
Adolescence- Critical Period 43.1, 57, 57.1, 57.4, P706
Adolescent P168, P705, P723
Adolescent Alcohol P49, P632, P647
Adolescent Alcohol Use P741
Adolescent Anxiety 38, 49.2, P113, P290
Adolescent brain P115
Adolescent Brain and Cognitive Development Study P121
Adolescent Brain Cognitive Development study P124, P161, P302
adolescent cannabis P517
Adolescent Depression 49.2, 57, P165, P252, P290
adolescent development P129
Adolescent PTSD P57
adolescent stress P575
Adolescents P236, P295
adult hippocampal neurogenesis P9, P382
Adult stem cells P392
Adverse childhood events P161, P296
Adverse life experiences P312
affective behavior 40.4, P388
affective components of pain P623
affective disorders P305
affective instability P32
African American P160, P522
Age of Onset P520
agency 43.4
Aggression P94, P101, P341, P390
Aging 14, 14.4, 18.3, P1, P5, P10, P14, P283, P437, P570, P657
AK-1402 P366
akathisia P351
Akt P481
Alcohol 50, P4, P444, P621, P626, P627, P631, P641, P646, P654, P655, P666, P672, P684, P692, P694, P710, P715, P721, P729, P730, P736
Alcohol Abstinence P725, P737
alcohol abuse P184, P610
Alcohol and substance use disorders P596, P606, P638, P720
Alcohol consumption P651
Alcohol dependence P751
alcohol drinking P688
Alcohol epigenetic marks P610
Alcohol Response P656
Alcohol Sensitivity P686, P691
alcohol use disorder 25.2, 52.4, P182, P588, P613, P622, P629, P630, P645, P651, P656, P667, P671, P678, P679
Alcohol Use Disorder - Treatment 50.3, P608, P614, P625, P643, P669, P681, P688
Alcohol use disorder and drug addiction 25, 34.4, P595
alcohol use disorders 25.3, P154
alcohol withdrawal P71, P612
allopregnanolone P311
allostatic load P164
Allosteric modulator P601
alpha 7 nAchR P540
alternative splicing P153
altruism P429
Alzheimer disease P3, P7, P397, P403, P408
Alzheimers disease P399
Alzheimer’s Disease 12, 42.2, P4, P154
AMPA receptors P306, P565, P569
Amphetamine P149, P717
Amygdala 7.4, 8.1, 21, 21.2, 21.4, 47, 47.2, 47.4, 55, 55.1, 55.2, P51, P62, P66, P85, P94, P104, P108, P120, P272, P291, P293, P307, P539, P630, P632, P654, P730, P736, P752
analgesia P460, P683
Anandamide P88
androgen deprivation 58.2
anhedonia 9.3, 52.3, P47, P176, P240, P244, P267, P330, P344, P356, P389, P478, P649
animal model 1, 1.3, 33.4, 48.1, P748
Animal Models 18.1, 31.2, 34.2, P176, P404, P698
anixety P478
anorexia nervosa P191, P192, P193, P195, P197, P200, P206
Anterior Cingulate Cortex (ACC) P389, P627, P678
Anterior insula P156
Anterior insula-prelimbic pathway P312
antibody P724
Antidepressant 52.2, P240, P298, P344, P355, P409
anti-depressant like action P361
Antidepressants P326, P354, P379
anti-gliadin antibodies (AGA) P546
antinociception P697
Antipsychotic 27.1, 53, P298, P489, P530
Antipsychotic drugs 51.2, P488
antipsychotic medication P350
Antipsychotic response P554
antipsychotics 27.3, 51.4, P212, P540, P561
Anxiety 30.3, 49, 52.1, P30, P34, P36, P42, P49, P55, P65, P70, P78, P81, P82, P83, P106, P126, P182, P262, P479, P605, P622, P654
Anxiety & PTSD 7.4, P40, P58
Anxiety and Depression 16.1, 27, 42, P130, P292
Anxiety and stress 31, P86, P725
Anxiety circuitry P86, P113
Anxiety development 38.2, 38.3
anxiety disorders P424
anxiety-like behavior P41
anxiety-like phenotype P23
anxiolytics P81
anxious distress P234
apathy 28
appetite regulation 39
Approach/Avoidance 40.1, P44, P263
arterial stiffness P93
Artifical transcription factors P218
associative learning 55.2
Astrocyte 35.1, P4, P211, P266, P500, P599, P612
Astrocyte-Blood vessel interaction P380
astrocyte-neuron interaction 35
astrocytes 18, 18.1, 35.2, P176, P215, P598
Attention P126, P167, P270
Attention Deficit Hyperactivity Disorder P433, P443
attention shifting P286
attentional bias P31, P55
Auditory fear conditioning 51.1, P63, P574
Auditory hallucinations 51.2, 51.3, 51.4
auditory perception 51, P574
Auditory striatum 51, 51.1, P574
Autism 5.3, 15.1, 33.1, 44, 44.1, 44.4, P109, P114, P116, P151, P439, P546
Autism & depression P433
autism spectrum disorder 33, 33.4, P166, P172, P179, P455, P569
Autism spectrum disorder and related syndromes 5, P129, P131
autism Spectrum Disorders P117, P150, P170, P174
Autoantibody P543
Autoimmune encephalitis P543
autonomic nervous system P57, P91
Autoradiography 27.1
aversion P265
Aversive Learning 56, 56.2, 56.3, P102
avoidance 56.1, P627
avoidant/restrictive food intake disorder P190
avolition 28, P504
Axon Initial Segment (AIS) P481
AXS-05 P227, P244
baclofen P159
Balb/c mouse P81
Bariatric Surgery P198
Basal forebrain P107
Basal Ganglia 31.2, P554, P744
basolateral amygdala 47.1, 55.3, P66, P107, P179, P381, P431, P468, P574, P663
BDNF P216, P445, P700
bed nucleus of stria terminalis P51, P84, P647
Behavior 36, P134
behavioral despair P213
behavioral economics P649, P699, P709
behavioral flexibility P105, P746
behavioral inhibition system P735
Behavioral Model 30, P201, P407
Behavioral Pharmacology 41.3, P86, P208, P368, P405, P458, P680
Behavioral Phenotyping P653
Behavioral Tasks P18, P433
Belief Updating P637
benzodiazepine P16
beta arrestin 2 P459
Biased signaling P601
big data P519
big data analysis P162
Binge alcohol use P607
binge drinking 50.3, P602, P641, P659, P702
Binge eating 39.3, P194, P469
Binge Eating Disorder 39, 39.3, P21, P204
Biobank P523
Biofeedback P57
Biology of aging P6, P13, P545
Biomarker P535, P611, P681
Biomarker analysis P299, P403, P436
biomarkers P320
Biomarkers for Risk Assessment 43.2
Biotypes P643
Bipolar Depression P247
Bipolar Disorder P120, P189, P217, P231, P234, P239, P254, P269, P270, P277, P283, P291, P293, P295, P303, P306, P310, P317, P329, P336, P339, P340, P353, P359, P364, P371, P482, P525
Bipolar I & II disorder P373
Bipolar I disorder P351
Blood vessel P215
Blood-Brain-Barrier P374, P666
BNST 25.3, P87, P622, P664
body dissatisfaction P199
Body Dysmorphic Disorder P415
body image disturbance P199
Body mass index P193
BOLD fMRI signal P277, P418, P631
Borderline Personality Disorder P469
Brain P206
Brain age P509
brain aging 24.3, P15
Brain Based Markers for Depression P402
Brain Circuits P20, P744
brain connectivity P207
brain connectome 5.4, P40
Brain development 42.1, P133
brain imaging P192
Brain Insulin Resistance 27, 27.1, 27.4
Brain Mapping P384
brain networks P209, P510
Brain nutrient sensing 27.3
brain proteomics P3
brain stimulation 8, 8.3, 19, P208
brain structure P302
brain transcriptomics P110
Brain-Based Predictive Modeling P499, P511
Brain-Behavior Relationships 30.4, 46
Brain-mediated mechanisms 27.3
breast cancer 58.3
bulimia nervosa P194
Buprenorphine P677
Buprenorphine-Naloxone P615
BXD mouse lines P253
Ca2+-permeable AMPA- type glutamate receptors P701
calbindin P483
calcium imaging P96, P216, P395, P421, P489
cAMP signalling P411, P561
canabinoid receptors P75
cancer 58, P296
cancer survival 58.2
Cannabidiol P174, P698
cannabinoid P705, P746
cannabinoid receptor type 1 P727
cannabinoids P683, P685
cannabis P145, P270, P586, P633, P650, P668, P683, P684
cannabis concentrates P684
cannabis use P295, P594
cannabis use disorder 26.3, P598, P683
capsulotomy 13.2
Cardiac Reactivity P310
Cardiometabolic Risk P69
cardiovascular P189
cardiovascular function P93
care coordination P677
cariprazine P83, P342, P343, P351
catecholamine 15.2
Caudate P123
Causal Modeling P43
CB1 receptor P90
CB2 receptor P560
CBT P276
Celecoxib P247
Cell adhesion molecules P652
Cell- and Circuit-selectivity P589, P639
central amygdala P595, P600, P721
central nucleus of the amygdala P318
cerebellum P550
Cerebral Blood Flow P156
Cerebral Cortex P744
cFos P369, P462, P659
c-Fos-expressing ensembles P753
CGRP P725
Chd1 33.1
Checklist 2
Chemobrain 58.2
chemogenetics 18.1, 44.4, P103, P151
chemokines P479
chemotherapy 58, 58.1
Child abuse and neglect P430
child and adolescent psychiatry P136
Childhood Adversity P11, P69, P651
childhood maltreatment P54, P636
Childhood trauma P46, P90, P145, P281, P321, P429
Childhood-onset schizophrenia P528, P529
Children and Adolescents P55, P143, P146, P171, P371
Cholesterol biosynthesis P4
choline P533
Cholinergic P434
cholinergic system P10, P596
chorea P398
choroid plexus 1.3, P23
CHRNA5 P655
Chronic corticosterone P268
Chronic diseases P327
chronic pain P59, P180, P688, P689, P715
Chronic social and non-social stress P253
chronic social defeat P373
chronic social defeat stress P112, P357
Chronic social stress P319, P380
chronic stress P211, P375, P391
Chronic unpredictable mild stress P376, P378
chronic unpredictable stress P222, P224
Chronic variable stress P221
chronotype P139, P482
cingulum P186
circadian rhythm P254, P401, P482
circadian rhythms P391
Circuit 47.2, 47.4
Circuit Development P292
circuit optogenetics P51, P111, P751
Circuitry-based approach 55.2, P659
Circulating cell-free mitochondrial DNA P223
claustrum 52.4, P21
Clinical Development P491
clinical efficacy P470
clinical high risk P498
clinical high risk for psychosis 43.3, P534, P549, P563, P576
Clinical high-risk of psychosis P509, P515
Clinical Neurobiology P457
clinical neuroimaging research 37, P308
clinical outcome prediction P193, P335
clinical prediction P287
Clinical predictors P346
clinical psychopharmacology P553
Clinical Subtypes P472
Clinical trial P25, P117, P119, P239, P400, P424, P494, P495, P614, P615
Clinical Trial Design 45, P450
Clinical Trial Methodology 8.2, P334
Clinical Trial Rating Methods P333
clinical trials P230
clinical trials methodology P28
Closed-Loop 8.3
Closed-loop control P94
Closed-loop stimulation P263
CNS Clinical Trials P298, P450, P491
cocaine 1.4, P611, P642, P663, P676, P701
cocaine addiction P592, P750, P752, P753
cocaine and opioid use disorders P584
cocaine self-administration P738, P747, P750
cocaine self-administration and reinstatement 55.3
cocaine sex differences P587, P716, P747
cocaine use disorder P443, P636, P644, P696, P706
Cognition 5.1, 18, 18.1, 24, 24.1, 24.4, 52.4, 53, P6, P124, P185, P246, P402, P408, P452, P496, P706, P712
Cognitive / behavioral flexibility P224, P500
cognitive and affective neuroscience 28
Cognitive biomarkers P229
cognitive control P501
Cognitive Control Cetwork P419
cognitive control network 21.2, 31.1
Cognitive Decline 24.2, 58.3
Cognitive dysfunction P571, P605
cognitive flexibility 7.1, P133
cognitive function P348, P532
Cognitive Functioning P499, P529
cognitive impairment 58, P222
Cognitive impairment associated with schizophrenia 24.3, 24.4, P503, P557
Cognitive impairments 24
Cognitive Impariment 14, 58.2, P503, P564
Cognitive Neuroscience 58.3, P43
cognitive reappraisal P53
Cognitive remediation P242
Cognitive test 24.2
cognitive training P119, P447, P452
Combat PTSD P27
Comorbidity P424
Co-morbidity P182
Complement component 4 P523
compulsive drug intake P610
Compulsivitiy P744
Computational Cognitive Neuroscience 30.2
computational ethology P330
Computational Genomics 35.3
Computational Methods P438, P514
computational modeling 3, 30.1, 30.3, 46, 56.1, P195, P284, P646
computational models of decision-making 16.4, P194
Computational Neuroscience 24.3, 30.4, P39, P513, P643
computational psychiatry 30.2, 30.3, 56.1, P56, P194, P287, P521
Concurrent Disorders P670
conditioned fear memory P377
conditioned inhibition of fear P96
conditioned place preference P592, P716
conflict of interest 4
Connectivity 21
Connectivity gradients P35, P100, P687
connectomics P446
consciousness P347
Consummatory behavior P702
Context P505, P733, P740
contextual fear P97
Continuous performance task P43
coordinated specialty care P551
COPD P581
copy number variants P110, P529
copy number variation P517
Correctional Psychiatry P670
cortex P668
cortical development P150
cortical plasticity 18.2
cortical thickness P54, P155
cortical thinning P121
Corticosteroids P14
corticosterone 34.1, P66
Cortico-striatal-thalamo-cortical Circuits 35.1
corticotropin releasing factor P609
Corticotropin-Releasing Hormone P94, P376
Cortisol P13, P38, P43, P311
Cortisol response to stress P245
COVID-19 38.3, 48.3, P91, P402, P503
COVID-19 pandemic P38, P58, P121, P262, P435
CpG Methylation P159
Craving 22.2, P182
c-reactive protein P544, P545
CRF P664
CRISPR 1.3
CROSS DISORDERS P188
CRP P72
CSF Biomarkers P13
Cue Reactivity 34, P614
cue-induced craving 26.2, P625, P634, P678, P688
cue-reactivity P621
Cytokine P247
cytokines P477, P546
cytoskeleton P489
D1 dopamine receptors 40.3
D2 dopamine and 5HT2A serotonin antagonists P356
D2 dopamine antagonists 27.1
D2 dopamine receptor P661
dACC P348
DBS 13.3, 31, 31.3, 31.4, P418
Decision Making 55.2, P195, P388, P390, P431, P468, P638, P712
deep brain stimulation 13, 13.1, 49, 49.4
Deep learning P439
Default mode network (DMN) 26.1, P258, P418, P576
defensive and motivated behaviors P107
delay discounting P441, P501
delta9-tetrahydrocannabinol P652
Delusions P521
Dementia 28
Dendritic spines 41.1
dentate gyrus P385
Depression 17, 27.4, 30.2, 30.3, 41.4, 42.2, 42.3, 52.4, P24, P60, P224, P230, P233, P245, P248, P250, P257, P260, P262, P274, P275, P276, P281, P294, P296, P297, P300, P308, P313, P316, P320, P322, P325, P326, P327, P328, P343, P345, P359, P368, P369, P372, P374, P375, P376, P380
Depression and Anxiety 30, P227
Depression model P204, P337, P366
Depression subtypes P228, P229
Derivative P366
Development 18.4, 49, P124
Developmental P122, P723
Developmental model P518
developmental origins 54, P8
Developmental Psychopathology 38.4, P128
Developmental Sensitive Period P133
developmental trajectories P154
Developmental trajectory P113, P115
Developmental transcriptome P153
diabetes P183
diagnosis P187
diffusion MRI 21.4
Diffusion Tensor Imaging (DTI) P567
diffusion tractography 31.4, P305
Diffusion Weighted Imaging P52
digital assessment 11, P167
Digital phenotyping 12, 16, 16.2, 16.4, P329, P333
digital psychiatry 42.3
digital therapeutic P129, P167
dimensional psychopathology P187
dimensions P187
dimensions of psychosis 7.3
dimethyltryptamine P425
discrimination 42.1
discriminative conditioning P96, P100
disinhibition P735
disorganization P512
Dissociation P352
diverse populations P416
Diversity P531
Diversity and Inclusion P169
DLPFC P272
DMT P425
DNA Methylation P54, P60, P77, P217, P301, P656
DOI P360
Dopamine 1.4, 7.3, 27, 27.2, 31.3, 40.3, 50.1, 50.2, 51, 51.1, 51.2, 51.3, 51.4, 55, 55.1, 55.2, 55.3, 56, 56.3, 56.4, 57.1, 57.2, P5, P19, P83, P105, P149, P203, P206, P207, P394, P432, P466, P542, P556, P559, P561, P574, P589, P593, P603, P609, P661, P687, P739, P740, P746, P748
Dopamine (D2, D3) receptors P356, P488
dopamine D2 receptors P561
dopamine D3 receptors P719
Dopamine D4 receptor P707
Dopamine function 55.4
Dopamine receptors P728
dopamine release P443
dopamine transporter 31.3
Dopaminergic neurons P489
Dopaminergic system 57
Dorsal anterior cingulate cortex P669
dorsal raphe P251
Dorsal striatum P203, P411, P590, P690, P738, P741
dorsolateral prefrontal cortex (DLPFC) P64, P153, P255, P534, P617
Dorsomedial striatum P573, P582
dose response P220
dose-response relations P323
DREADDs P583
drift diffusion model P286
drinking 50.2
drosophila 33
drowsiness P463
drug addiction P634
Drug choice paradigm P676
Drug Development P399, P704
Drug Discovery - new approaches P76, P363, P379, P503
drug discrimination 50.3, P691
Drug Poisonings 22.1
Drug Relapse 34.1, P606, P699
drug repurposing P439
Drug Seizures 22.1
drug self-administration P709, P735
drug targets P437
drug-drug interaction P709
Drug-naive P538
Dual orexin receptor antagonist (DORA) P615
Dual Orexin Receptor Antagonists P581, P696
Dynamic Causal Modeling P258, P415
dynamic functional connectivity P687
Dynorphin P21, P745
Dysphoria P24, P460
E/I imbalance P348
early brain development 38.2, P140
early childhood 5, 5.1
early improvement P342
Early intervention P552
early life 58.1
Early life adversity 14.3, P144, P434
early life anxiety P41
early life infection P155
Early life stress (ELS) P69, P111, P112, P115, P160, P161, P164, P177, P178, P385, P587, P663
early onset psychosis P122, P528
Early Parental Loss 40.4
Early Phase Drug Development P408
early psychosis 24.1, P305, P499, P501, P535, P536
early-life adversity 9.3, P9, P163, P318, P385
Early-life experience P142
eating behavior 39
Eating disorders 3, P190, P191, P194, P197, P202, P206
ecological momentary assessment P32, P35, P37, P168, P333, P451, P689
Ecological validity 46
Education and Training 20
EEG biomarkers 8, P130, P228, P252, P334, P450, P557
EEG connectivity P154, P267
EEG electrophysiology P352, P448
EEG/ERP electrophysiology P191, P274
Effective Connectivity P30, P415
Efference copy/corollary discharge P502
Efficacy and safety P226
effort based decision making task P389
Effort-Cost Decision-Making P620
electric field modeling P325
electroconvulsive therapy 17, 17.4, P266, P288, P325, P332, P382, P465
Electroencephalography (EEG) 43.1, P130, P169, P232, P267, P456, P502, P567, P570, P571, P572, P611
Electron Microscopy P548
Electronic cigarette (e-cigarette) P586, P722
Electronic Health Record 45
electrophysiology P220, P391, P485, P487, P706
elevated plus maze 52.1
EMA P284
Emergency Department P410
Emerging Therapies P399
Emotion Circuitry 9, P39, P97
Emotion Perception P291
Emotion regulation P248, P279
Emotional dysregulation P275, P469
Emotional empathy P430
Emotional regulation 21.1, P57, P271
Emotional stress P369, P628
Empathy P508
Emraclidine P566
endocannabinoid system P117, P188, P594, P747
Endocannabinoids 34.1, 47.3, 56, 56.4, P46, P50, P90, P380, P559, P626, P628, P715, P727, P732
energy metabolism P163
engram 47.3, P16
ENIGMA Working Group P519
enkephalin P251
Entropy P142
environmental risk factors 5, 29
epidemiology P152, P520
Epigenetic P401, P587
epigenetic age acceleration P11, P54
epigenetic clock P11
Epigenetic Modification 1, P595
epigenetic regulation P606
Epigenetics P1, P115, P213, P455, P592, P656, P657
epilepsy 33.1, P396, P406
Epitranscriptome P654
ERK P88
Escitalopram P247
esketamine 17.2, P237
Esketamine nasal spray P236
estradiol P68, P664
estrogen receptors P664
ethanol intake P700
ethical issues 4
ethics 36, 54
Ethnicity P531
excitation-inhibition balance P151
excitatory and inhibitory imbalance hypothesis 44.4
Excitatory Synapses P76, P422
executive function 30, 58.1, P652
exercise P1
exosome P223
exploration P432
exploration-exploitation tradeoff P432
explore-exploit dilemma P6, P284
Exposome P124, P164
Exposure therapy P25
Expression Polygenic Risk Score P300
extended-access self-administration P701
Extended-release naltrexone P616
Externalizing behavior 14.2
Extinction P87, P603
Extinction learning 41.1, P627
Extinction recall P29
extracellular matrix P211
Extracellular vesicles 15.1, 15.2
Extrapyramidal symptoms P351
extrasynaptic glutamate P220
eye tracking P170, P473, P679
eye-blink P463
F-18 PET Imaging 38.2, P12
Facial emotion processing 27.4, P55, P255, P456, P629
facial expression analysis P265
familial risk of bipolar disorder P371
family history of alcohol use disorder P658
family study 5.3
fast scan cyclic voltammetry P591
fatigue P281
Fatty acid amide hydrolase P304, P594
Fear P51, P87, P104, P108
Fear conditioning 7, 23, 47.1, P46, P78, P97, P100, P107, P369, P642
Fear conditioning and extinction 47.2, P85, P103
Fear extinction 41, P92
fear generalization 55.4
Fear learning 18.2
fear memory 9.4, 47
Fear Processing P415
fear-potentiated startle P36, P89
feeding 50.2
feeding behavior 50, P205
female 16.2
Fentanyl 22, 22.1, 22.2, 22.3, P583, P624, P640, P665, P692, P695, P709
fetal alcohol spectrum disorder P401
Fetal Brain Development 14.2, P477
fetal programming P148
FGF21 P375
FGF-21 P235
fiber photometry 56.3, P149
first episode psychosis P513, P551, P555
first-episode psychosis P550
Fluid homeostasis P17
fluorodeoxyglucose P442
fluoxetine P357
fMRI biomarkers 8, 16.1
fMRI Effective Connectivity P629
fMRI Functional Connectivity P32, P125, P293
focused ultrasound 13.3, P260, P365
food cues P190, P198
forced swim test P355
Forensic Psychiatry P670
formal thought disorder P512, P513
fragile X syndrome P159, P169
frequency optimization P322
frontopolar cortex P617
Frontostriatal P305
frontotemporal dementia P18
frustration P286
functional and structural neuroimaging 5, 58, P63
functional brain networks P124
functional connectivity P111, P200, P260, P554
functional data analysis P465
functional genomics P383
functional magnetic resonance spectroscopy P533
Functional MRI (fMRI) 8.1, 9.3, 26.3, 26.4, 38.1, 44.4, P6, P30, P45, P47, P48, P55, P65, P68, P99, P132, P143, P173, P190, P192, P248, P261, P384, P428, P430, P449, P454, P457, P504, P508, P614, P621, P623, P625, P627, P633, P644, P648, P661, P671, P678
functional neuroimaging 40.1, P157, P275, P280, P457, P494
G protein-coupled receptors P601
GABA P341, P474, P506
GABA MRS P506, P538
GABA neuron P106, P612
GABA-A P79
GABA-A receptors P324, P368
GABAergic interneurons 7.1
Gabapentin P703
galanin P445
gamma oscillation P570
gamma oscillations P365, P518
gamma, theta, delta P448, P464
Gamma-band auditory steady-state response (ASSR) P567
GDF-15 P235, P375
Gender P531
Gene co-expression networks 6.1, P297, P482
Gene environment interaction P164
gene expression 6, 58.1, P150, P471, P587
gene therapy P485
Gene-by-sex interaction P189
Gene-environment interaction P253
Generalizability P537
generalized anxiety disorder P39, P79, P99
Genetic Association Analyses P523
Genetic association study P156, P525, P653
genetic mouse model P72
Genetic Testing P528
Genetic variation P198, P436
Genetically encoded sensor P411
Genetics 33, P340
Genome-wide association studies P522
Genomics P188
geriatric P65
Ghrelin P614, P702
Glia 33.1
GLP-1 receptor agonist 39
Glucagon-like Peptide-1 39.1, 39.3
glucocorticoid receptor P222
glucocorticoid receptor gene P177
Glucocorticoid signaling P312
Glucocorticoids 34, P22, P266, P604
GluN2A recepter subunit P219
glutamate P64, P216, P278, P345, P353, P377, P458
glutamate GABA 43.1, 57.1
glutamate GABA co-release P273
glutamate transport P49
glutamatergic synapses P548
glutathione P283
glutathione (GSH) P353
glycine P213
glymphatic system P17
glyoxalase 1 P368
goal-directed behaviors 35.2, P745
Gonadal Hormones P619
GPCR P421, P562
GPCRs P427
GRAB-5HT P690
graph theory P138
Gray matter volumes P156
grid cell P7
grief 40.1
GRIN1 mutation P396
GRIN-related disorders P395
Group 2 Innate lymphoid cells P23
growth mixture modeling P313
Guidance cues 57.4
Guideline 2
Gut Microbiome 14.1, P147, P315, P316, P478, P667
Gut-Brain Axis P172
GWAS P416, P436, P441, P524, P532
habenula 49.2, P273, P596
Habenula and Periventricular Thalamus 49, 49.1
Habit P413, P738
habit formation P708
Habit Reversal Therapy P413
habituation 8.4
Hallucinations P521
hallucinogen P358
Headache P407
HEAL Initiative P674
Health Disparities P152
Healthy controls P667
heart rate variability P44, P93
heritability P199, P463
Heroin P599
heroin seeking P639
heroin self-administration P639, P711
High Density Sleep EEG P563
high fat diet P697
high-throughput screening P76, P114
hippocampal connectivity P387, P576
Hippocampal neurogenesis P210
Hippocampal volume P146
Hippocampal-prefrontal P37
Hippocampus 7, 7.4, P1, P35, P62, P108, P266, P297, P434, P448, P494, P516, P539, P619, P749
Hippocampus Shrinking P409
hippocampus-mPFC pathway P101
hIPSCs P22
Hispanic/Latinos 42, 42.2, P326, P651
histone deacetylases P455
histone variants 1.1
HIV P712
HIV and Inflammation P321, P586
HIV-Associated Neurocognitive Disorder P181, P185
HMGB1 P86
H-MRS P348
Hoarding Disorder P419
Homeostatic Plasticity 33.1
Homosexuality P578
hormonal contraceptive use P476
HPA axis 47.4
HPA axis dysregulation P312
hPSC 35.4
Human Clinical trial P26
human connectome P200
Human Genetics P440, P657
Human Laboratory Study P618
Human Neuroimaging 3, 8.2, 10, 19, 25.3, 40, 49, P40, P65, P145, P184, P189, P325, P455, P549, P620, P622, P637
human pluripotent stem cells P487
human postmortem brain tissue P110
Huntington’s Disease P398
Hyperarousal P126
hypothalamus 23.2, P196, P445
ibogaine P720
IGF-1 P114
IL-25 P23
Imaging P444, P556
imaging genetics P302, P440
Immune P320, P321
Immune Biomarkers P301, P547
immune function P72
immune markers P546
Immune responses P218
immune system 14.3, P471
immunity P8
Immunometabolism P544
immunotherapy P403
Impulsive behavior P208
impulsivity 30.1, P34, P125, P441
in vivo P461
in vivo calcium imaging 41.1, 51.2, 56.2, P98, P377, P743
in vivo electrophysiology 7.3
In vivo fiber photometry 47.3, 55, P19, P111, P179, P203, P363, P411, P593, P638
In vivo Imaging P379
incentive motivation P251
incentive salience 9.2, P658
incubation of cocaine craving P593
Incubation of drug craving 34, 34.2
incubation of oxycodone craving P590
Independent Component Analysis 16.2, P673
individual differences 9.2, P731
individual variation P635
Induced pluripotent stem cells (iPSCs) P484, P485, P527, P578
Infancy 5, 38.4
Infant Behavior 38, P186
Infant Brain 5.3, 38, 38.1, P186
Infant Emotionality 38, 38.3, P186
infant neuroimaging P140
inflammation 14.1, 14.2, P4, P50, P92, P217, P247, P322, P327, P370, P371, P544, P545, P564, P580, P665
Inflammatory Markers P274, P311
inhibition 30.1
Inhibitory control 57.4, P34, P128, P270, P419, P621
inhibitory interneuron 52.1, P585
Inhibitory interneurons 47.3
innovative methods P426
inpatient P308
insomnia P248, P581
Insula P147
insular cortex P21, P202
insulin 27, 27.2
insulin resistance P11
Intergenerational transmission of trauma P54
interleaved TMS/fMRI P272
Intermittent Access self-administration 1.4
internal capsule 13.1
internalizing disorders P32, P130, P138
interoception P191
interpeduncular nucleus P106, P596
intestinal microbiome P172
Intoxication P682
intracranial EEG P272, P448
intracranial self-stimulation P722
intravenous drug self-administration P583
intrinsic motivation P504
Intrusions P52
irritability 38.4, P286
IV- Ketamine 17.4, 31.1, P25, P230, P450
kappa agonist P460, P720
kappa opioid receptor P714, P745
Kappa Opioid Receptor Antagonist P240
KarXT P492, P493
Ketamine 31, P70, P246, P332, P337, P345, P357, P370, P379
Ketamine/esketamine 17, P288
Ketogenic diet P269, P697
Ketones P686
Kidneys P349
KINECT-HD2 P398
kratom P680
Kynurenic acid P503
kynurenine metabolism P579
Kynurenine pathway P546
Lactate-to-Pyruvate ratio P235
Language P326, P514
Laser Capture Microdissection P486
LASSI P181
Late-life Depression P223
Lateral Habenula 49.4, P201, P729
Learning 55, P104, P206, P271
learning and memory P433, P452
learning generalization P447, P641
Learning Health System P555
legislation 4
Lesions 13, P200
Levetiracetam P494
life-span 18
light-sheet microscopy P734
limbic system P664
Lipid metabolism P300
Lithium P349, P406
local field potentials P208
locomotor activity P716
loneliness P507
longitudinal P339
longitudinal multimodal imaging P41
longitudinal study 38.2, P186, P634, P648
long-term 17.2, P237, P343
long-term results 41.4
long-term safety 17
Loss 40, 40.3, 40.4
low-field MRI 43.3
LPS P12
LSD P459
LSD microdosing P347
lumateperone P231, P234
Lymphatics P17
M1 and M4 Muscarinic Receptors P493
machine learning P130, P161, P193, P232, P288, P306, P328, P332, P335, P537
machine learning classification P208, P330
Machine learning clustering P171, P256, P282, P289
Magnetic Resonance Imaging 9, P340, P509
magnetic resonance spectroscopy P64, P506
magnetoencephalography 43.4, P246, P258
Major depression P266, P333
Major Depressive Disorder (MDD) 21.2, 21.3, 49.4, P22, P210, P211, P214, P221, P225, P226, P227, P228, P231, P234, P237, P238, P240, P242, P243, P244, P249, P264, P267, P268, P285, P289, P295, P299, P304, P306, P307, P323, P331, P332, P334, P342, P343, P350, P355, P362, P373, P383, P423, P436, P547, P569
maladaptive feeding P201
marginalized youth P132
marmoset P518
Maronutrient P163
mast cells P70
Master Observational Trial 45
maternal behavior P163
maternal brain P430
Maternal Depression P473
maternal genotype P579
maternal immune activation 48.1, P148, P477
maternal mental health P140, P430
maternal stress P297
mating 23.2
Matrix Metalloproteinases P598
MC-100093 P700
MCH neurons P611
MDMA 41, 41.1, 41.2, 41.3, 41.4, P29, P456
mechanism 24, P220
Mechanistic Clinical Trial P248
medial entorhinal cortex P7
Medial Orbitofrontal Cortex 56
Medial Prefrontal Cortex 18.1, 34.1, 41.1, P100, P103, P105, P121, P133, P149, P259, P378, P395, P396, P602, P747
medio-dorsal thalamus P534
Medium Spiny Neuron P603, P748
MEG P466
mega-analysis P123
melanopsin P254
Memory 18.2, 42.2, P1, P8, P16, P35, P434
Memory and Learning P393, P461
Memory Bias P48, P641
Memory Enhancing P461
memory reconsolidation P752
Mendelian Randomization P524
Menstrual Cycle P474
Mental Health and Health Disparities 42, P171
Mental health disorders P152
Mesocorticolimbic system P127
mesolimbic circuitry 56.3
mesolimbic reward circuitry P314
meta-analysis P350, P533
Metabolism P134, P217
metabolomics P166, P315
metabotropic glutamate receptor P605
Metabotropic glutamate receptor 2 (mGluR2) P382
Methadone P685
methamphetamine 50, P347
Methamphetamine Self-Administration 50.1, P605
Methylation P657
methylone P26
methylphenidate P207, P687
mGlu5 P585
MIA 48
mice 7, P149, P388
mice imaging 44
Microbiome 14.2, 14.4, P166
Microbiota-gut-brain axis 14, P316
microcircuit processing 47.3
microglia 18, 18.3, 18.5, 25.2, 40.4, P73, P114, P176, P222, P318, P319, P517, P645, P662, P668, P718
MicroRNA P299
migraine P407
mild cognitive impairment due to AD P181, P242
Mild Traumatic Brain Injury P410, P442
mindfulness P74
miniscope P640
minocycline P552
miRNAs 15.2
mismatch negativity P95, P568
Misophonia P126
Mitochondria P2, P213, P223, P378, P409, P417, P575
mitochondrial DNA P417
mitochondrial DNA copy numbers P177, P373
mixed features P231, P234
Mobile technology 16.3, 42.3, P167
Model systems P393
moderators P32
Molecular Genetics P393
molecular mechanisms 15
Molecular profiling P169
Monetary reward P48, P184
Monoamine P366
monoclonal antibodies P608
Mood 31.3, 49
mood and anxiety disorders P358
mood disorder P362
mood disorders 9, 10, P58, P236, P273, P486
Moral distress 54
Morphine sensitivity P253, P697
mother-child dyads P33, P38
motivated behaviors P205
motivation 57.2, P271, P573, P740
Motor Evoked Potentials P541
motor learning P412
Mouse and monkey models P453
mouse brain 32, P465
Mouse Circuit Dissection 51
Mouse models P180, P391, P607, P668
mPFC P112, P464, P468
MR imaging P198, P519
MR spectroscopy P386
MRI P307, P423, P444, P516, P539, P742
MRSI 43.1, P554
Mu opioid receptor P251, P355, P582, P589, P693, P713
multi-echo fMRI P397
multimodal biomarkers 11
multimodal data 43
Multimodal Neuroimaging P289, P402, P536
Multimodality neuroimaging 43.4
Multi-omics P62, P319, P681
multiple sclerosis P392
multivariate pattern analysis P325
mu-opioid receptor agonist P704
muscarinic M4 P566
Muscarinic receptor agonist P492
Myelination 18.2
myo-inositol P533
N,N-Dimethyltryptamine (DMT) P80
N1 P502
N-acetylcysteine P353
nalfurafine P460, P714
nalmefene P714
naloxone 22, P692
Naltrexone P345
natural language processing (NLP) P328, P512, P513, P514
Natural setting 46
naturalistic drug cues P634
Navacaprant P240
Negative Affect P260, P506, P632, P647
negative reinforcement P19
Negative Symptoms 24.1, P122, P490, P491, P501, P508, P509, P544, P571
neighborhood resources P132
Neighborhood Socioeconomic Deprivation P146
network analysis P512
network based statistic (NBS) P636
network control theory P285
network neuroscience 43, 43.2, P30
Neural activity 32.3
Neural circuit and animal behavior 55.4, P390
neural circuits 31, P66, P98, P385
neural complexity P347
Neural connectivity 44.4, P262
Neural mechanism 53
neural plasticity P354
neural populations P577
neural progenitor cells 15.2
Neuroactive Steroids P474
neuroanatomy 39, 39.1, P440
neurobiological subtypes 44
neurocircuitry 21.4
Neurocircuits 13
Neurocognitive assessment 12, 30.2
neurocognitive function 58
neurodegeneration P394
Neurodegenerative Disease P17, P400
neurodegenerative diseases 11
neurodevelopment 43.3, P162, P529
neurodevelopmental and behavioral deficits P132
Neurodevelopmental Disorders 15, 15.1, 18.3, 56.1, P109, P118, P157
neuroeconomics P183, P388
Neuroendocrine P68
Neuroendocrine responses P134
neuroendocrinology P446, P476
neuroepigenetics 1.1
Neurofeedback P257
neurogenetics P485
neuroimaging P309, P372, P510, P535
neuroimaging biomarkers 16, 26, P379, P550
Neuroimmune 18.3, 25
neuroimmune activation P73
Neuroimmune communication 18.4, P70
neuroimmune mechanisms P662
neuroinflammation P12, P197, P586, P608, P700, P742
Neurokinin P730
Neurological and Psychiatric Disorders P405
Neuromelanin-sensitive MRI P5, P386, P537, P542
Neuromodulation 3, 8, 26.3, P200, P337, P397
neuronal culture P216
Neuronal ensembles P753
Neuronal Oscillations 8.3, P243
neuronal remodeling P222
Neuron-astrocyte interactions 35.1, 35.4, P49, P180
neuropathic pain P404
neuropeptide S P624
neuropeptides 23.2, P730
neurophysiology P324
Neuroplasticity 32.4, 52, P129, P233, P264, P365, P405, P409, P462
neuroprotection P15
Neuropsychiatric Disorders P560
Neuropsychiatric Disorders [Schizophrenia, Parkinson’s Disease, Major Depressive Disorder] P546
Neuropsychiatric symptoms (NPS) 29
neuropsychopharmacology P465
Neuropsychopharmacology (NPP) P368
Neuroscience 2
Neurosteroid P165, P475
neurosteroids 34, P337
Neurostimulation P255
neurosurgery for psychiatric disorders 13.2
neurotensin 50, 50.1, 50.2, 50.3, P601
neuroticism P125
Neurotoxicants 29
Neurotrophins P421
Neurovascular P374
Neurovasculature P215
new drug development P358
nicotine P591, P655, P689, P710, P722
nicotine addiction 1.3, P623, P673, P708
nicotine dependence 26.1
Nicotine exposure 1
nicotine withdrawal P673
nicotine/substance use disorder P613, P662
NINDS P674
NMDA Antagonists P219, P352
NMDA glutamate receptors P605
NMDA modulators P558
NMDA Receptor P220, P324, P395, P396, P543
NMDA Receptor Antagonist P227
N-methyl-D-aspartate P244
Nociceptin/orphanin FQ P695
nociception P715
non addictive analgesics P674
non pharmacological interventions P449
Non-hallucinogenic P361
Nonhuman Primate Models 38, 38.2, P41, P607
Non-human primates 21.4, P278
noninvasive brain stimulation 8.4, P243, P374, P617
Non-invasive Neuromodulation P225, P260
Nonlinear analysis P572
Non-opioid, Non-addictive Therapeutics P59
Noonan syndrome P158
noradrenaline P91
noradrenergic signaling P483
Noradrenergic System P618, P702
norepinephrine P5, P98
norepinephrine transporter P175
novel antidepressant P337
novel assessment tools for clinical trials P28
Novel coronavirus (SARS-CoV-2) P471
novel endpoints P75, P426
novel methods P331
novel object recognition P461
novel therapeutics P197
NPSR1 P624
NREM sleep P42, P579
Nucleus Accumbens 56.3, P84, P102, P205, P314, P378, P597, P598, P678, P730, P732, P746, P751
nucleus accumbens core P377, P561
Nucleus Accumbens Shell P251, P748
nucleus reuniens P178
nutrient sensing 27
Obesity 27.2, P11, P198, P449, P530, P545
Obesity and eating disorders 39.3, P204
observational fear learning P33
obsessive-compulsive disorder (OCD) 13.2, 13.3, 13.5, 31, 31.1, 31.4, 35, 56.2, P413, P414, P416, P417, P418, P420, P428
Obsessive-compulsive personality traits P414
OCD phenotypes 35.1
older adults P99
oligodendrocytes 18, 18.2, P392
omega-3 P552
Omega-3 Fatty Acid P118, P131
Open neuroscience P672
Operant behavior P468
opioid P345, P583, P718, P742
Opioid addiction P604, P628, P635, P637, P677, P685, P694, P724, P726, P734, P748
Opioid craving P711
opioid dependence 1, 1.3, P616, P748
opioid overdose P692, P724
opioid receptor P427, P699
opioid receptor expression P584
opioid receptor system P82
opioid reward P713
opioid side-effects P713
opioid tolerance P582, P733
Opioid treatment 22.2, P724
opioid use disorder 22.2, 26.4, P597, P613, P618, P665, P675, P727, P749
opioid withdrawal 22, P697, P698, P718
opioids 34.2, P680, P695, P703, P719
Opioid-sparing effects P685
optical biosensors P63
optical imaging P216
Optimism P637
optogenetics 31.2, 47.4, P98, P453, P734
Oral Self-Administration P640, P708
orbitofrontal cortex (OFC) 47.1, P431, P588, P590, P624, P634, P741
orexin P204, P696, P721
orexin receptor antagonist P675
orexin/hypocretin P84, P675
organic cation transporters P717
Organoids P484, P527
orphan receptors P561
Orthologs P221
outcomes P426
ovarian hormones P67, P587, P710
ovarian steriods P313
Overdose P749
oxidative stress P564, P575, P608
oxycodone P699
oxytocin 40.1, 41, 48.1, P82, P429, P694
PACAP P725
Pain P623, P685
pain models P580
Pain sensitivity P737
pair bond 40, 40.3, 40.4
Pallidum P442
pandemic P677
panic P71
parabrachial nucleus P647, P725
Parasympathetic nervous system 14.3
paraventricular nucleus of the hypothalamus P376
paraventricular nucleus of the thalamus 7.3, 9.2, 9.3, 9.4, P142, P290, P427, P751
paraventricular thalamus 7.2, 9, 49.2, P732
Parkinson’s disease P206, P394, P400
Partial agonist Ligands P707
parvalbumin P585
parvalbumin interneurons P133, P575
Parvalbumin neurons P518
patient centered research design P75
Patient Reported Outcomes 58.3, P336, P426
pattern separation P9
Pavlovian conditioning 55.3, P641, P690
PDE10A P553
pediatric 8.2, P412
Pediatric Bipolar Disorder P339
pediatric irritability P136
Perceived stress P261
Percieved control P261
periaqueductal grey (PAG) P103, P113, P737
Perimenopausal Depression P314
Perimenopause P314
perinatal depression P475
perinatal mental health P472
Perinatal stress P472
peripheral biomarker P13, P144
Peripheral blood marker P137, P214, P373
Peripheral neuromodulation P327
persistent avoidance P414
personalized medicine 16, 26, P245, P617, P643
PET Imaging P116, P214, P304, P453, P540, P569, P660, P661, P704, P728
PET Imaging Study P443, P565, P673
Pharmacodynamics P79
Pharmacogenetic Response P530, P681
pharmacogenomics P298
Pharmacokinetic and Pharmacodynamic P219, P365, P652, P686
pharmacokinetics P80, P425
Pharmacology P348, P363, P602
pharmacotherapy 1, 1.3, P748
Phase 1 P233
phase 1 study P352
Phase II clinical trial P228, P229, P245
Phase III trial P495
Phosphodiesterase-4 (PDE4) P12, P359
physical activity 42.2
Physical dependence P698
Physical exercise P15
Physician-Scientist 20
PKCdelta P600
placebo-controlled trial P476
placenta 15, 15.1, 15.2, P471, P477
plasticity 57.1
platelet derived growth factor P713
pleiotropy analysis P532
Polygenic risk for inflammation P155
polygenic risk score 6.1, P61, P154, P158, P164, P297, P302, P310, P340, P514, P522, P653, P658
polysubstance abuse P703
Positive Affect P633
positive allosteric modulators P79
Positive symptoms P563
positron emission tomography (PET) 25.2, P175, P423, P442, P466, P556, P566, P594, P645
post hoc analysis P342, P351
post treatment efficacy P616
Post-infectious Sequelae P58
Postmortem P526
Postmortem Brain Tissue 32, P60, P77, P438, P486
Postmortem Brain Tissue Gene Expression 6.1, P196, P480
Postmortem Human Brain Tissue 6, 35, P548
postpartum P378
postpartum depression P312, P470, P471, P472
Posttraumatic stress disorder 8.4, P27, P35, P37, P43, P74
poverty 14.2
prairie voles 33, P338
pre/post neuroimaging 19
Precision Imaging P303, P387
Precision Medicine 45
Precision Medicine for Depression 16.1
Precision Medicine for Mood Disorders 16.4, P336
precision psychiatry 17.4, 26, P228, P229, P309, P414
Preclinical P359, P560
Preclinical Alzheimer’s Disease 12
Preclinical models and endpoints P315, P461
Preclinical pharmacology P80, P219, P363, P407, P557
Predator Odor P691
Prediction P43, P261
Prediction error P47
Predictive Biomarker P170, P232
Predictive Coding P95, P513
Predictive Models 30.4
predictors of response 17.4
prefrontal cortex 43.1, 57.1, P14, P53, P62, P165, P224, P292, P548, P577, P585, P619, P639, P705, P736, P743
pregnancy 15, 15.1, 54, P89, P115, P118, P478, P479
premature treatment discontinuation P551
Prematurity P138
premenstrual dysphoric disorder P311, P474
Premorbid functioning 24.2
Prenatal alcohol exposure P648
prenatal anxiety 5.2
Prenatal Cannabis Exposure P134
Prenatal Drug Exposure 5.2, P145
Prenatal exposure 48, P8
Prenatal immune exposures 48.3
prenatal poverty 5.2
Prenatal SSRI Exposure P473
prenatal stress 5.2, 14.1, 48.3
Prenatal Stress Model 14.1, P131
prescribing P555
Prevention P242
primates P540
Prodromal Psychosis P497, P521
prodrome P498
progesterone P662
Pro-inflammatory cytokines 14, 14.4, P479
prolonged grief 40, 40.1
prophylactic P370
protective factors P498
Protein engineering 32.3
Proteomics 32, 32.3, 32.4, P109, P320, P524, P536, P588, P597
proton magnetic resonance spectroscopy P353
Proximity-labeling enzymes 32.3
Psilocybin 52, 52.3, 52.4, P346, P387, P400, P420, P459, P558
Psilocybin analog P226
PSPP P674
Psychedelic P405
Psychedelic effects P420, P457
Psychedelic medicine P95, P212, P328, P720
Psychedelic therapy 52, P176, P457, P558
Psychedelics 52.1, 52.2, P80, P238, P309, P315, P337, P358, P360, P362, P387, P400, P425, P459, P462, P711
psychiatric disorders P187
psychiatric genetics P416
psychiatric hospitalization P650
Psychiatric measurement 2
psychological distress P38
psychometric properties P281
psychometric tests P287
Psychoneuroimmunology P317, P321
psychopathology P118, P155, P187
Psychoplastogens P361
psychosis 51.2, 51.3, P3, P492, P498, P502, P505, P511, P522, P526, P537, P543, P552, P559, P564
Psychosis spectrum symptoms P122, P137, P515
Psychosis-Risk P482, P504, P516, P520, P552
Psychosocial Intervention P670
Psychosocial outcomes P536
Psychostimulant P424, P661, P723
psychostimulants P680
Psychotic Disorders P507
Psychotropic Medications P310
PTSD 7, 7.1, 7.2, 8.1, 9.4, 21.3, 23, 41, 41.2, 41.4, 47, P22, P24, P25, P26, P29, P33, P43, P45, P47, P50, P52, P60, P61, P64, P67, P72, P73, P77, P87, P89, P91, P92, P93, P598
puberty 57, 57.2, P127
publication policies 37
pulvinar P518
punishment P738
punishment learning 30.3, P750
pupil P463
pyramidal neuron P153
Quality control P162
quality of life 58.2, P227, P261, P677
Quantitative Electroencephalography (qEEG) P252
R-(-)-ketamine P370
Race P531
Race disparities 42.3, P61, P522
Racemic Ketamine and metabolites P726
racial ethnic minority 42
Racial minorities P296
Randomized Double-Blind P226
Randomized-Controlled Trial P118, P243
raphe P752
Rapid depression treatment P279
Rapid-acting Antidepressant 17, P238
Rare genetic variants P525
rat P722
Rats P458
Real World Data 45
real-time fMRI neurofeedback 21, 21.1, 21.2, 21.3, 21.4, P53, P135, P271
Real-world clinical outcomes 34.4, P555
reappraisal P99
receptor heteromerization P693
receptor tyrosine kinase P421
REDD1 (DDIT4, RTP801, Dig2) P224
Regeneration P392
Regulatory 2
Reinforcement learning 30, P591, P712
Reinforcement-based decision-making P644
relapse P87, P752
relapse biomarkers P285
relapse circuits 34.2
Reliability P384
REM sleep P85, P362, P579, P696
Renal P349
Renewal P603
repetitive behavior 35.1, P131
repetitive transcranial magnetic stimulation (rTMS) 13, 13.1, 13.4, 26, 26.1, 26.2, 26.3, 26.4, 43.4, P225, P232, P256, P282, P669
replicability 37
Replication P537
Research domain criteria (RDoC) P344, P536
Resilience 14.4, 32.4, P635
respiratory depression P692
response inhibition P141
Resting and task fMRI P160, P387, P454
resting state brain imaging P331
Resting State Connectivity 44, 44.1, P123, P502
Resting State Functional Connectivity 5.2, 5.4, 8.1, 9.3, 26.1, 49.1, 49.2, P27, P127, P142, P145, P290, P384, P414, P497, P511, P541, P550, P636
Resting state networks P565
Resting State, Functional MRI 49
Resting-state fMRI P37, P128, P151, P161, P207, P276, P613
retention 20
retrograde tracing P659
Reward P47, P207, P265, P273, P428, P476, P501, P633, P702, P739, P753
reward and aversion P427, P638
Reward Anticipation P690
reward circuitry P356
Reward functioning P135
reward learning P432, P731
Reward Liking P330
reward neural circuitry P262
reward prediction error P638
reward processing P31, P141, P376, P389, P648
Reward self-administration 50
Reward Sensitivity P127
Reward-based decision-making P646
Ribosome-heterogeneity P221
Risk P646
Risk and Resilience P498
Risk factors P520
risk genes 32
Risk Stratification 11
Risk-Based Decision-Making P364
Risky decision-making P268
RNA binding protein P393
RNA methylation P654
RNAseq 6, 35.4, P10, P151, P370, P394, P480, P486, P526, P583, P711
rsfMRI functional connectivity P565
rumination P280
safety learning P96
Safety/tolerability P470
Salience P202
Salience network P669
Schizophrenia (SCZ) 24, 24.2, 26.1, 27.3, 35, 35.3, 43, 43.2, 43.4, 51.4, P153, P359, P428, P480, P481, P484, P486, P487, P490, P492, P493, P494, P495, P496, P508, P509, P510, P514, P519, P523, P524, P525, P526, P527, P531, P532, P538, P540, P541, P543, P544, P545, P546, P547, P556, P561, P565, P566, P567, P569, P570, P571, P572, P573, P577
Schizophrenia novel treatment P553, P562
Schizophrenia Spectrum Illness 11, 14.4, 28, P520, P554
Schizophrenia subtypes P3, P546
School Environment P146
Selective Serotonin Reuptake Inhibitors (SSRIs) P63
self administration and CPP P674
Self-Administration 22, 22.3, P703, P717, P719
self-control P620
self-harm P478
Self-medication with psychedelics P95
semantic speech graph P512
Sensitive Period P113
sensitization 7
sensor technologies 46
Sensors 36
sensory processing 33.4, P412, P591
serious mental illness P650
Serotonin P63, P111, P259, P292, P385, P607, P690
serotonin 2A P362
Serotonin 5-HT2A Receptor P80, P212, P358
Serotonin 5-HT2C Receptor P175, P719, P729
sex and estrous cycle effects P584
sex differences 22.3, 25, 57.4, P8, P13, P16, P33, P50, P84, P103, P148, P150, P174, P178, P196, P211, P215, P275, P364, P434, P440, P511, P591, P596, P622, P626, P630, P635, P645, P676, P683, P691, P701
Sex-specific effects 25.3, P15, P180, P341, P422, P662
Sex-specificity P253
sexual orientation P578
Sexual trauma P296
Sibling design P172
Simulated Driving P682
Single nucleus RNA sequencing P62, P604
single-cell genomics P210
Single-cell RNA sequencing 1.4, 35.3, P301, P610
single-nuclei sequencing P734
single-nucleus RNA-seq P110
Single-unit electrophysiology ex vivo P427
Single-unit electrophysiology in vivo P18, P741
SK3 calcium-activated potassium channels P483
Skin conductance responses P33
sleep 42, 42.1, P329, P391, P580, P611
sleep architecture P581
sleep deprivation P85
Sleep disturbances P451, P665, P696
sleep spindles P42
slice electrophysiology P51, P354, P396, P582, P652, P732
slow oscillation P42
slow-wave activity P264
slow-wave sleep P85, P563
smartphone 16
Smartphone-based app 16.4, P413
SMS text messaging P326
SNAP25 P406
SNP P317
sociability P101
Social and behavioral deficits P338, P467
social anxiety P631
social anxiety disorder P28
social attachment 33.4, P467
Social Attention P473
Social Behavior 14, 23, 41, 41.2, 48.1, 56.1, P102, P174, P179, P218, P255, P390, P445, P456, P647, P672
social cognition 21.1, 24.4, P468
social cognitive skills training P129
Social Competence P464
Social defeat stress 57.4, P338
social deficits P144, P166
social determinants of health P146
Social determinants of health inequity 38.1, P171
social dominance P259
Social Drinking Motives P672
social fragmentation index P576
Social Functioning P508
Social hierarchy P736
social isolation 23.2, P500, P736
Social Isolation Stress P626
social jet lag P139
social motivation 40.3
social neuroscience 41.3
Social responsiveness P140
Social reward P48, P649
social stress 57, P84
Social support P435, P472
social-evaluative stress P630
software P438
solutions 37
Somatosensory processing P258
Somatostatin P408, P602
spatial memory P338
spatial multi omics P383
spatial representation P7
spatial transcriptomics P20, P196, P210, P383, P438
Spectroscopy P278
sphingosine 1-phosphate receptor P404
spinogenesis P76
Spontaneous Release P406
SSRI P120
State dependence 26.3
statistical methods P337, P438
Stimulants P173, P454, P719
Stress 25, 39.1, 47, 47.4, P23, P88, P168, P182, P209, P215, P372
Stress and Trauma P68, P91, P184
stress resilience P45, P259, P714
stress-enhanced fear learning (SEFL) 7.2
striatum 27.2, 31.3, P48, P104, P526, P609, P718, P739
Stroke P412
Structural MRI 43.3, 49.1, P120, P131, P134, P137, P147, P162, P256, P282, P289, P529
structural neuroimaging P158
Structural neuroplasticity P361
structure of psychopathology P128
subcortical volume 5.1
Subjective cognitive decline 12
Subjective Cognitive Impairment P682
Sugjective States P56
Substance abuse P648, P660
Substance abuse disorders 1, P653, P707
substance use P437
substance use disorder 1.5, 10, 26, 49, P601, P617, P636, P714, P728, P734, P743, P745
Substance-related disorders 26.2
Suicidal behavior 16.3
suicidal ideation 16.2, P168, P288, P451
Suicidal ideation and behavior assessment tool 16.3
suicide P168, P250, P258, P277, P284, P301, P302, P341, P435
Suicide attempt 21.1
Suicide Mechanisms P308
Suicide prediction P308
suicide prevention P279
sulforaphane P490
Surgery P2
Sustained remission P616
Synapses 32, P292, P546
synaptic density P116, P660
Synaptic Function P488
Synaptic Plasticity 35, 50.1, 52.2, P2, P76, P324, P377, P395, P421, P422, P585
Synaptogenesis 35.2
systems biology P109
systems neuroscience P446, P576
TAAR1 P495, P562
Tac2 23
Target engagement P119, P352
targeted cognitive training P496
task fMRI 30.4, P507
TCB-2 P360
telemetry P580
telescoping effect P701
telomere length P177
temperament 38.3
temperature regulation P163
temporal lobe P52
testosterone P127
Test-Retest Reliability P143, P280
Thalamo-cortical Interactions P577
Thalamus P539, P744
Thalamus - Reticular nucleus P178
THC P347, P682, P699, P712
theta burst transcranial magnetic stimulation P279
Theta-burst stimulation P36, P225, P255, P263, P671
Threat Conditioning P20, P44
Threat reactivity P68, P94, P98, P143
thymus P144
Thyroid P349
tianeptine P355, P409
TNF-alpha P700
Tobacco Smoking P594, P689
tolerance P212, P679
Toll-Like receptors (TLRs) P477
Tourette syndrome 31.2
Trajectories P294
Trajectory Modeling P43
trajectory of symptom improvement P323
Transcend Therapeutics P26
transcranial current stimulation P267
transcranial direct current stimulation (tDCS) 8.4, P27, P242, P447, P452
transcranial magnetic stimulation (TMS) 8.1, 8.2, 13.4, P24, P36, P263, P272, P323, P324, P374, P448, P571, P671
transcranial photobiomodulation P397
Transcriptome P663
Transcriptomics 1, P166, P209, P301, P549
transcutaneous auricular vagus nerve stimulation (taVNS) P322
Transdiagnostic P136
transgenic rat model P600
Translating Innovation P426
Translational Animal Models 3, 10, P268, P364
Translational biomarker approaches to drug development P238, P450
Translational Neuroscience 10
Translational Research 23
Translational studies P675
translocator protein (TSPO) 25.2, P214, P645
Trauma exposure P31, P43, P45, P74
Traumatic Memories P37
Traumatic stress P691
treatment 24, P556
treatment adherence P239
Treatment allocation P332
treatment duration P323
treatment outcome 19
treatment prediction 31.1
Treatment Resistant Depression 17.4, P219, P225, P249, P357, P386
treatment response P342, P550
Treatment-refractory depression P233
Treatment-resistant depression 17.2, P235, P237, P246, P256, P282, P289, P317, P346, P384
treatment-resistant schizophrenia P533, P542
Triazole P707
TSPO and [11C]PBR-28 PET P73
TWAS P657
twins P199
twin-study P463
Two-photon calcium imaging P363, P599, P624
Type 2 diabetes 27.3
Type I interferon signaling 18.4
Ulorant 53
Ulotaront P495
ultra high-risk youth P515
Ultra-high field MRI P257
Ultrasonic vocalization (USV) model P83, P640
ultrasonic vocalizations P144
Unbiased Effect Size Estimation P467
unpredictability P142
Vagus Nerve Stimulation P249, P327
valbenazine P398
Valence P104, P381
valporic acid P349
Valuation P56
Value-based Decision-Making P183, P192, P284
Vasopressin 1b antagonist P245
ventral hippocampus 7.1, 7.3, 52.1, P16
Ventral Pallidum 56.4, P381
Ventral Tegmental Area (VTA) 50.1, 55.3, P204, P257, P269, P604, P639, P721
ventrolateral prefrontal cortex P291, P293
ventromedial prefrontal cortex P96
vesicular glutamate transporter (VGLUT) P394
veterans P58, P294, P671
Vigilance P126
Viloxazine P175
viral tracing 39.1
virtual reality 8, 8.4, P24, P27, P31, P57
visual attention P505
visual perception P505
Visual Processing P95
vitamin D P443
Voltage-Gated Calcium Channel P483
voltammetry P609
Voxel-Based Morphometry (VBM) P475
Vulnerability P635
Waste clearance P17
Weight loss treatment P449
White Matter P52
White Matter Development 5.4, P41
White matter microstructural alteration P567
Whole exome sequencing P525
whole genome sequence P528
Whole-Brain Rodent Imaging 1.3, P388, P390, P659, P733
Williams syndrome P156, P157
withdrawal 1, 1.1, 1.3, 22.3, P748
women P93, P621
women’s health 54, P321
Women’s Mental Health P67
working memory P5, P14, P36, P119, P246, P428, P577, P706
World Trade Center Rescue and Recovery Work P45
Worry P30, P65, P99
xanomeline 53, P492, P493
Xylazine 22, 22.1, 22.3, P709
young adults P303, P633
youth P310, P497
Zaleplon P458
zebrafish 33
Zuranolone P470
α5 GABAA positive allosteric modulator P408
β-arrestin P212
Rights and permissions
About this article
Cite this article
ACNP 62nd Annual Meeting: Keyword Index. Neuropsychopharmacol. 48 (Suppl 1), 530–543 (2023). https://doi.org/10.1038/s41386-023-01759-1
Published:
Issue Date:
DOI: https://doi.org/10.1038/s41386-023-01759-1